CENTERVILLE, Mass., Dec. 12, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT)(the "Company") is pleased to announce plans for a 2013 rollout for its patented FDA Cleared Viratech 400 and RX Air units. To date the Company has spent over a decade and several million dollars developing the best air purification technology in the world. The device offers the most cost-effective system for treating all forms of indoor air pollution on the market today, with a cost of ownership which typically runs about 25 cents per day. In the next few months the Company will be executing on five main areas:

Top Tier Retailers

Internet and Specialty Retailers

Medical Sales

Enforcing & Licensing our Patented Technology

International Expansion

Top Tier Retailers

With the recent signing of DPG Distribution, one of the nations' leading distributors to top tier-retailers such as Costco, Sears, Best Buy, and a host of others, UV has the opportunity to select retail outlets that can educate the consumer to the unique benefits the Viratech UV -400, along with the importance of Indoor Air Quality overall. A key factor in this deal was DPG's relationship with funding sources such as Wells Fargo for P.O. financing. The biggest hurdle for smaller Companies working with large retail exposure is financing large orders, so the DPG relationship offers considerable advantages.

Internet and Specialty retailers

UV Flu feels it has a host of opportunities in this segment. This space not only includes large internet retailers such as Groupon and Amazon, it can also include specialty internet sites related to allergies, salons, pets, or travel. Infomercial or home-shopping type sites also offer an incredible area of opportunity.

Another area we plan to spend a considerable amount of resources on is the Sleep Market. "The $25 billion sleep market is almost 4 times bigger than the market for air-purification, and customers have overwhelmingly praised the Viratech for its ability to treat all forms of Indoor Air Pollution, which has been shown in clinical studies to be the key environmental factor in causing sleep problems. Customers feel they sleep better with our device, and the added ability to kill airborne bacteria and other contaminants is another major positive. We expect a significant increase in demand for our products, as we announce major endorsements, well as national and international retail availability through outlets and television," said Mr. Lennon.

Medical Sales

"We are also committed to gaining increased traction on the medical side," said Mr. Lennon. "We are in talks with interested parties in helping us gain access to the reimbursable and non-reimbursable side of the hospital and residential medical device market, and we think with our installed base of products in almost 600 hospitals worldwide, we have the potential to make some major inroads."

"Almost 99,000 people died from hospital-associated infections last year, along with 529,038 surgical site infections in 2010. UV light is now becoming the accepted standard for fighting surface and airborne contaminants. The Viratech UV-400 is the only pure UV based, FDA cleared technology for fighting airborne infection approved for sale in hospitals in the US, China and India. We offer an incredible cost advantage over UV based systems designed to fight surface contamination, which typically can run from $80,000 to $135,000 per unit," said Mr. Lennon.

Our markets for the medical side include emergency room waiting and treatment areas, nurseries, oncology, patient rooms and transplant areas.

Enforcing & Licensing our Patented Technology

The Company is going to pursue finding a top tier law firm to review our patents and related technology for licensing revenue and potential enforcement of our patent portfolio. The company has patents in the US and Worldwide. Our patents have several key factors that make our technology unique and we hope to capitalize on that. We will update shareholders as information becomes available.

International Expansion

The Company is actively seeking additional distributors for its entire product line in the Mideast, Europe and India, along with a host of other countries.

We are convinced that the best way for investors to learn about us as an investment is to try our product. We have found that once an investor uses our technology they understand not only the need but the value proposition. Any shareholders or interested investors interested in buying a Viratech UV-400 unit at a discounted price, can call the Company at 877-FLU-KILL.

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the Viratech UV-400.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer; manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.